Inventor · disambiguated record
Eliot Ohlstein
Also filed as: OHLSTEIN ELIOT · OHLSTEIN ELIOT H · OHLSTEIN ELIOT HOWARD
18 granted patents·13 pending applications·401 citations·filing 1987–2025
95Inventor score
Files withVELICEPT THERAPEUTICS INC10SMITHKLINE BEECHAM CORP6VTV THERAPEUTICS LLC6BOEHRINGER MANNHEIM PHARM CORP4SMITHKLINE BECKMAN CORP3
Top patents by PatentIndex Score
31 records- 0193US10456406B2Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limbVTV THERAPEUTICS LLC·Filed 2018·Granted Oct 29, 2019·9 cites·11 claims
- 0293US9968613B2Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limbVTV THERAPEUTICS LLC·Filed 2016·Granted May 15, 2018·12 cites·14 claims
- 0393US9907767B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2017·Granted Mar 6, 2018·10 cites·42 claims
- 0493US9487493B2Use of a PPAR-delta agonist for treating muscle atrophyVTV THERAPEUTICS LLC·Filed 2014·Granted Nov 8, 2016·17 cites·20 claims
- 0592US10350182B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2018·Granted Jul 16, 2019·6 cites·16 claims
- 0692US9522129B2Pharmaceutical CombinationVELICEPT THERAPEUTICS INC·Filed 2013·Granted Dec 20, 2016·14 cites·16 claims
- 0790US11096946B2Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limbVTV THERAPEUTICS LLC·Filed 2019·Granted Aug 24, 2021·2 cites·10 claims
- 0890US9956194B2Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2015·Granted May 1, 2018·18 cites·60 claims
- 0990US5393772AUse of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferationBOEHRINGER MANNHEIM PHARM CORP·Filed 1993·Granted Feb 28, 1995·99 cites·32 claims
- 1089US5308862AUse of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferationBOEHRINGER MANNHEIM PHARM CORP·Filed 1993·Granted May 3, 1994·88 cites·3 claims
- 1184US10668034B2Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2019·Granted Jun 2, 2020·1 cites·16 claims
- 1284US5453436ATreatment of athereosclerosis using, carbazolyl-(4)-oxypropanolamine compoundsBOEHRINGER MANNHEIM PHARM CORP·Filed 1994·Granted Sep 26, 1995·62 cites·3 claims
- 1383US10751311B2Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2018·Granted Aug 25, 2020·2 cites·16 claims
- 1483US8642661B2Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonistsCALTABIANO STEPHEN·Filed 2011·Granted Feb 4, 2014·15 cites·22 claims
- 1576US2022072005A1Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limbVTV THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 1675US5643939AUse of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferationBOEHRINGER MANNHEIM PHARM CORP·Filed 1994·Granted Jul 1, 1997·38 cites·3 claims
- 1774US2025360139A1Use of a ppar-delta agonist for reducing loss of muscle strength, muscle mass, or type i muscle fibers in an immobilized limbVTV THERAPEUTICS LLC·Filed 2025·Application pending·0 cites
- 1865US2020246292A1Pharmaceutical compositions and the treatment of overactive bladderVELICEPT THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1965US2007129415A1Method of Treating Isolated Systolic HypertensionBROOKS DAVID P·Filed 2007·Application pending·0 cites
- 2065US2005113431A1Method of treating isolated systolic hypertensionSMITHKLINE BEECHAM CORP·Filed 2004·Application pending·0 cites
- 2158US2003045561A1Method of treating isolated systolic hypertensionSMITHKLINE BEECHAM CORP·Filed 2002·Application pending·0 cites
- 2257US4935438ADopamine-β-hydroxylase inhibitorsSMITHKLINE BECKMAN CORP·Filed 1987·Granted Jun 19, 1990·4 cites·6 claims
- 2357US2004105861A1Use of factor XIIIa inhibitors to treat atherosclerosisSMITHKLINE BEECHAM CORP·Filed 2003·Application pending·0 cites
- 2454US2017035716A1Method of using solabegronVELICEPT THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 2548US4882348A2-(aminoalkylthio)imidazoles as dopamine-β-hydroxylase inhibitorsSMITHKLINE BECKMAN CORP·Filed 1987·Granted Nov 21, 1989·4 cites·9 claims
- 2645US2001005723A1Method of treating isolated systolic hypertensionSMITHKLINE BEECHAM CORP·Filed 2001·Application pending·0 cites
- 2745US2002107177A1Use of factor XIIIa inhibitors to treat atherosclerosisSMITHKLINE BEECHAM CORP·Filed 2002·Application pending·0 cites
- 2842US2017348288A1Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladderVELICEPT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2942US2017348263A1Compositions and methods of using modified release solabegron for lower urinary tract symptomsVELICEPT THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3039US2002040045A1Method of treating isolated systolic hypertensionSMITHKLINE BEECHAM CORP·Filed 2001·Application pending·0 cites
- 3134US4912226AIntermediate to dopamine-β-hydroxylase inhibitorsSMITHKLINE BECKMAN CORP·Filed 1989·Granted Mar 27, 1990·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Eliot Ohlstein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →